Research Article
Effect of Moringa oleifera Leaf Capsules on Glycemic Control in Therapy-Naïve Type 2 Diabetes Patients: A Randomized Placebo Controlled Study
Table 1
Baseline clinical and laboratory characteristics of MO leaf and placebo group.
| | MO leaf
| Placebo
| value |
| Male sex | 7 (44%) | 10 (56%) | 0.48 | Age (years) | | | 0.07 | Body weight (kg) | | | 0.91 | BMI (kg/m2) | | | 0.14 | Duration of DM (months) | 18 (1–48) | 18 (2–60) | 0.72 | Family history of DM | 14 (88%) | 12 (75%) | 0.65 | Hypertension | 7 (44%) | 10 (63%) | 0.29 | Antihypertensive agents (%) | 7 (22%) | 9 (28%) | 1.00 | Dyslipidemia | 9 (56%) | 13 (81%) | 0.13 | Lipid lowering agents (%) | 5 (16%) | 11 (34%) | 0.28 | FPG (mg/dl) | | | 0.14 | HbA1C (%) | | | 0.39 |
|
|
MO leaf, Moringa oleifera leaf; BMI, body mass index; DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1C, hemoglobin A1C.
|